Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s):  BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.


CSE:BIOV - Post by User

BioVaxys Technology Corp.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(371)
•••
Post by moneywagonon Dec 29, 2021 3:55pm
162 Views
Post# 34268798

BIOV WONDER WHY SO MANY CEO FORUM CONTEST PICK BIOV? tee hee

BIOV WONDER WHY SO MANY CEO FORUM CONTEST PICK BIOV? tee hee
 
@Filipino @Goldfinger Great interview! I know it's been mentioned here before the background of CEO James Passin and his large stake in the company. If they raise funds down here at these levels, I will have to consider averaging down to add to my position. IMO the SP could really only go up from there. Cheers.
 
2
 
@Acelove $NIOV will triple in price by summer 2022!
 
0
 
@Acelove $BIOV
 
0
 
@Silvertoes This is the presentation that Dr Berd presented at the World Vaccine and Immunotherapy conference:https://biovaxys.com/wp-content/uploads/2021/12/World-Vaccine-Congress-11-21-Berd-Biovaxys.pdf
 
1
 
@Silvertoes Nice to see that he had the time to review 20 slides and get into some of the details that are so encouraging and exciting
 
1
 
@ryguyfry Nice new interview on twitter
 
0
 
@snow_ball they need to correct the ticker for the interview article, should be BIOV instead of BIO.
 
1
 
@Filipino @snow_ball Yes. Definitely a mistake with the ticker symbol.
 
0
 
@rahul @goldfinger, that is a great writeup article, thankyou. I did not fall asleep and read the entire article. I like to nominate @goldfinger to the FDA panel!!!!
 
1
 
@Goldfinger Thank you @rahul, I'm glad you enjoyed it.
 
2
 
@olimagne #stockpickingcontest $PYR $HPQ $BIOV
 
1
 
@Revolution Lots of support on the stock picking contest already! $BIOV
 
1
 
@Revolution #stockpickingcontest $BIOV $BIOV $BIOV
 
0
 
@Silvertoes I like it @revolution
 
1
 
@snow_ball today is the deadline for tax loss selling
 
0
 
@Revolution Yippee! Still can’t believe I got some for $0.21!
 
0

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities